Company news
Percheron Therapeutics Limited (ASX:PER) news
Percheron Therapeutics Limited news releases on 6ix. Latest, Sep 18, 2019: Positive preliminary results from ATL1102 DMD Phase II trial
Press releases — page 3
Positive preliminary results from ATL1102 DMD Phase II trial
September 18, 2019
ATL1102 for DMD European regulatory interactions
September 2, 2019
Acromegaly Early Access Program Status Update
August 26, 2019
Phase II DMD clinical trial on track for dosing completion
July 24, 2019
Phase II clinical trial in DMD Fully Enrolled
May 23, 2019
Phase II clinical trial in DMD Update
April 3, 2019
Placement to Accelerate Development of ATL1102 in DMD
March 12, 2019
Pause in trading
March 10, 2019
Response to ASX Price and Volume Query
October 16, 2018
Full Year Statutory Accounts
August 29, 2018
First Patient Dosed in Phase II DMD Clinical Trial
August 28, 2018
ANP initiates ATL1102 Phase II clinical trial in DMD
July 15, 2018
ATL1103/atesidorsen Early Access Program Progress Update
June 14, 2018
ATL1103 Phase II trial results published in leading journal
May 23, 2018
Response to ASX Price & Volume Query
May 14, 2018
$5 Million Capital Raising Completion
May 3, 2018
Entitlement Offer Booklet
April 6, 2018
Placement Completion and Entitlement Issue
April 5, 2018
Institutional Placement and Rights Issue
April 3, 2018
ATL1102 Ethics Committee Approval for DMD
February 27, 2018
ATL1103/atesidorsen Early Access Program - Update
February 25, 2018
ATL1103/atesidorsen Early Access Program Agreement
December 21, 2017
ATL1102 for MS and DMD Update
December 18, 2017
ATL1102 Black Hole MS data to be presented at MS Conference
August 29, 2017
ATL1102 for Multiple Sclerosis Phase IIb trial Update
July 26, 2017
Antisense Therapeutics to enter clincial development in DMD
June 26, 2017
ATL1102 for MS Phase IIb IND submitted to the FDA
June 25, 2017
Positive effects with ATL1102 on MS Black Hole lesions
June 15, 2017
ATL1103 Update
May 17, 2017
ATL1102 for MS Phase IIb Investigational New Drug Submission
April 23, 2017
Market and Technology Update
March 23, 2017
ATL1103 Patent Update
February 23, 2017
ATL1102 for MS - Progress Update
February 15, 2017
Appendix 3C
December 7, 2016
Bonus and New Options Offer Prospectus
November 28, 2016
ATL1102 for Multiple Sclerosis - Progress Update
November 3, 2016
Capital Management Initiatives - Update
October 11, 2016
ATL1103 Higher Dose Study
October 10, 2016
Company Update
August 25, 2016
Positive Results Achieved from ATL1103 Higher Dose Study
July 26, 2016
ATL1103 Granted Orphan Drug Designation in Europe
June 27, 2016
ATL1102 for Multiple Sclerosis - Update
June 17, 2016
Antisense Technology Update
June 1, 2016
Company Strategy Update
May 23, 2016
Orphan Drug designation from FDA for ATL1103 in Acromegaly
May 12, 2016
ATL1103 Higher Dose Study - Update
May 9, 2016
ATL1103 Deed of Settlement, Termination and Transfer
April 29, 2016
ATL1102 for MS FDA Response to Phase IIb Study Plans
March 30, 2016
COR-004/ATL1103 Project Update
March 8, 2016
ATL1103 Data Presentation at Scientific Conference
February 11, 2016